SCHEMBL2634191

SCHEMBL2634191

CN(c1ccccc1CBr)S(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
CLK2 P49760 1/20 0.42
AURKB Q96GD4 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.40
JAK2 O60674 1/20 0.39
PTK2 Q05397 1/20 0.39
MEN1 O00255 2/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
CYP19A1 P11511 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 1/20 0.38
C5AR1 P21730 1/20 0.37
CDK1 P06493 1/20 0.37
CDK2 P24941 1/20 0.37
CDK5 Q00535 1/20 0.37
CDC42BPA Q5VT25 1/20 0.37
SRPK1 Q96SB4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28040740 0.86 KMT2A (0.44) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL10229066 0.85 KMT2A (0.49) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL30621311 0.81 KMT2A (0.46) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL646441 0.81 KMT2A (0.46) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL1291311 0.81 KMT2A (0.46) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL646500 0.81 KMT2A (0.50) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL16580719 0.81 KMT2A (0.46) KMT2ACLK2AURKBCLK4ALDH1A1
Hydrochloric Acid SCHEMBL30468480 0.80 KMT2A (0.45) KMT2ACLK2AURKBCLK4ALDH1A1
Hydrochloric Acid SCHEMBL15333616 0.80 KMT2A (0.45) KMT2ACLK2AURKBCLK4ALDH1A1
SCHEMBL16570034 0.79 KMT2A (0.44) KMT2ACLK2AURKBCLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633173-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC (US) 2014-01-21 US disclosed
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. 2013-11-07 US disclosed
US-8501936-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC. (US) 2013-08-06 US disclosed
EP-2438066-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES Cephalon, Inc. (US) 2012-04-11 EP disclosed
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. (US) 2010-12-09 US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives JAK2, JAK1, JAK3 KMT2A 1114/4885CLK2 539/4885AURKB 1300/4885
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CCNA1, CCNY, RB1 KMT2A 1262/4885CLK2 1088/4885AURKB 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.